Sandoz Q3 2026 Canadian Generic Semaglutide Commercial Launch Readiness in Focus After Health Canada Multi-Manufacturer Approval Sequence
Sandoz Group AG's preparations for a Q3 2026 Canadian commercial launch of generic semaglutide came into sharper focus over the weekend as Health Canada continues reviewing seven remaining generic submissions filed after the April 28 Dr. Reddy's and May 1 Apotex approvals. Sandoz signaled in late 2024 it would launch a Canadian generic semaglutide in 2026 when the active-drug patent expired; the company's filing is currently under Health Canada review with commercial readiness contingent on the agency's review timeline. Industry analysts expect Sandoz to enter the Canadian market with pricing 45-90% below the brand Ozempic CAD $300-400/month range, putting Sandoz generic pricing in the CAD $30-200/month tier (~$22-145 USD/month). The Canadian generic market is a five-year preview of what will hit the US after December 2031 patent expiry; watch what Ontario, BC, and Quebec formulary committees decide on listing terms over the next 90 days.